Results 61 to 70 of about 682 (125)

Clinical Characteristics During and After COVID‐19 Infection Among Healthcare Workers During the First Wave of Omicron in Chongqing, China

Immunity, Inflammation and Disease, Volume 13, Issue 1, January 2025.
Our study provides a comprehensive depiction of the clinical symptoms experienced by healthcare workers during and after SARS‐CoV‐2 infection in China's Omicron wave, shedding light on the intricate interplay between these symptoms and offering novel insights into the physiological impact of SARS‐CoV‐2 on human health.
Haoling Tang, Zhiwei Chen, Tianquan Huang, Pingping Yu, Qiao Tang, Yue Qiu, Yunling Xue, Jing Tang, Nan Cai, Hong Ren, Mingli Peng, Peng Hu   +11 more
wiley   +1 more source

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

The Role of Ursodeoxycholic Acid Administration During the COVID‐19 Pandemic: A Questionnaire Survey

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2025, Issue 1, 2025.
In December 2022, China classified COVID‐19 as a category B infectious disease. This ended 2 years of close epidemiological surveillance of COVID‐19. The objective of this questionnaire was to assess the infection status in the COVID‐19 pandemic since December in Henan Province, China, and the prevalence of infection in people who were taking ...
Cheng Zhou, Ran Jia, Jinqiu Yang, Tong Liu, Xiaoyan Liu, Lin Yang, Wenxia Zhao, Jess Vergis   +7 more
wiley   +1 more source

Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies

Influenza and Other Respiratory Viruses, Volume 18, Issue 12, December 2024.
ABSTRACT Enterovirus‐D68 (EV‐D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV‐D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV‐D68 positive.
Nida Kalam, Vinod R. M. T. Balasubramaniam   +1 more
wiley   +1 more source

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study

BMC Infectious Diseases
Background Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients.
Zhiguo Zhou, He Zheng, Gui’e Xiao, Xiangping Xie, Jiaxi Rang, Danhong Peng   +5 more
doaj   +1 more source

A Study on the Efficacy of Early Application of Azvudine in Viral Myocarditis under the Epidemic

Journal of Medicines Development Sciences
Objective: To explore the efficacy of early application of Azvudine in patients with viral myocarditis during the epidemic. Methods: Sixty patients diagnosed with "infection complicated with myocarditis" in our hospital from December 2022 to December 2023 were selected and randomly divided into an intervention group and a control ...
Minjie Wu, Linlin Tan, Anjian Yan
openaire   +1 more source

Azvudine (FNC): a promising clinical candidate for COVID-19 treatment [PDF]

Signal Transduction and Targeted Therapy, 2020
Yu, Bin, Chang, Junbiao
openaire   +2 more sources

Efficacy and Safety of Azvudine in Patients With COVID‐19 in China: A Meta‐Analysis of Observational Studies

The Clinical Respiratory Journal
ABSTRACTBackgroundAzvudine (FNC) is a novel small molecule antiviral drug for treating COVID‐19 that is available only on the Chinese market. Despite being recommended for treating COVID‐19 by the Chinese guidelines, its efficacy and safety are still unclear.
Tao Dong, Wentao Zhang, Tingting Wu, Yongxiang Ge, Qi Yang, Jia Xu, Yuna Liu   +6 more
openaire   +3 more sources

Masthead: (View 3/2025)

VIEW, Volume 6, Issue 3, June 2025.
wiley   +1 more source

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context

EClinicalMedicine
Summary: Background: Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe infection.
Shuxia Wang, Jin Sun, Xin Zhang, Man Li, Bangguo Qin, Miao Liu, Nan Zhang, Shengshu Wang, Tingyu Zhou, Wei Zhang, Cong Ma, Xinli Deng, Yongyi Bai, Geping Qu, Lin Liu, Hui Shi, Bo Zhou, Ke Li, Bo Yang, Suxia Li, Fan Wang, Jinling Ma, Lu Zhang, Yajuan Wang, Li An, Wenhui Liu, Qing Chang, Ru Zhang, Xi Yin, Yang Yang, Qiangguo Ao, Qiang Ma, Shuangtong Yan, Haili Huang, Peng Song, Linggen Gao, Wenning Lu, Lining Xu, Li Lei, Keyu Wang, Qi Zhang, Qing Song, Zhijian Zhang, Xiangqun Fang, Yao He, Tianzhi Li, Ping Zhu   +46 more
doaj   +1 more source